BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17762628)

  • 1. Bladder cancer biomarkers: current developments and future implementation.
    Alvarez A; Lokeshwar VB
    Curr Opin Urol; 2007 Sep; 17(5):341-6. PubMed ID: 17762628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer.
    Herman MP; Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF
    Minerva Urol Nefrol; 2008 Dec; 60(4):217-35. PubMed ID: 18923359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of tumor markers in urologic consultation for screening, diagnosis, and follow-up of bladder cancer].
    Lorenzo Gómez MF
    Actas Urol Esp; 2003 Feb; 27(2):110-6. PubMed ID: 12731325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for the detection of bladder cancer.
    Ross JS; Cohen MB
    Adv Anat Pathol; 2001 Jan; 8(1):37-45. PubMed ID: 11152093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular markers in bladder cancer: a critical appraisal.
    Konety BR
    Urol Oncol; 2006; 24(4):326-37. PubMed ID: 16818187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary markers in the everyday diagnosis of bladder cancer.
    Dal Moro F; Valotto C; Guttilla A; Zattoni F
    Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focus on urinary bladder cancer markers: a review.
    Ecke TH
    Minerva Urol Nefrol; 2008 Dec; 60(4):237-46. PubMed ID: 18923360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers.
    Bangma CH; Loeb S; Busstra M; Zhu X; El Bouazzaoui S; Refos J; Van Der Keur KA; Tjin S; Franken CG; van Leenders GJ; Zwarthoff EC; Roobol MJ
    Eur Urol; 2013 Jul; 64(1):41-7. PubMed ID: 23478169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and emerging bladder cancer urinary biomarkers.
    Parker J; Spiess PE
    ScientificWorldJournal; 2011 May; 11():1103-12. PubMed ID: 21623456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New molecular markers for bladder cancer detection.
    Quek ML; Sanderson K; Daneshmand S; Stein JP
    Curr Opin Urol; 2004 Sep; 14(5):259-64. PubMed ID: 15300145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of seven screening methods in the diagnosis of bladder cancer.
    Sun Y; He DL; Ma Q; Wan XY; Zhu GD; Li L; Luo Y; He H; Yang L
    Chin Med J (Engl); 2006 Nov; 119(21):1763-71. PubMed ID: 17097029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-invasive diagnosis bladder cancer: new molecular markers and future perspectives].
    Musquera M; Mengual L; Ribal MJ
    Arch Esp Urol; 2013 Jun; 66(5):487-94. PubMed ID: 23793766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas.
    Schultz IJ; Kiemeney LA; Karthaus HF; Witjes JA; Willems JL; Swinkels DW; Gunnewiek JM; de Kok JB
    Clin Chem; 2004 Aug; 50(8):1425-8. PubMed ID: 15277352
    [No Abstract]   [Full Text] [Related]  

  • 14. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
    Mahnert B; Tauber S; Kriegmair M; Nagel D; Holdenrieder S; Hofmann K; Reiter W; Schmeller N; Stieber P
    Clin Chem Lab Med; 2003 Jan; 41(1):104-10. PubMed ID: 12636058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Urine Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy.
    van Kessel KEM; de Jong JJ; Ziel-van der Made ACJ; Roshani H; Haensel SM; Wolterbeek JH; Boevé ER; Oomens EHGM; van Casteren NJ; Krispin M; Boormans JL; Steyerberg EW; van Criekinge W; Zwarthoff EC
    J Urol; 2020 Jul; 204(1):50-57. PubMed ID: 31985322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.
    Raspollini MR; Luque RJ; Menendez CL; Bollito E; Brunelli M; Martignoni G; Montironi R; Cheng L; Blanca A; Baroni G; Minervini A; Lopez-Beltran A
    Hum Pathol; 2016 Nov; 57():78-84. PubMed ID: 27473264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer].
    Szarvas T
    Magy Onkol; 2009 Dec; 53(4):385-9. PubMed ID: 20071311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survivin: a promising biomarker for detection and prognosis of bladder cancer.
    Margulis V; Lotan Y; Shariat SF
    World J Urol; 2008 Feb; 26(1):59-65. PubMed ID: 17962949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis.
    Weikert S; Christoph F; Schrader M; Krause H; Miller K; Müller M
    Int J Cancer; 2005 Aug; 116(1):100-4. PubMed ID: 15761870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers.
    Eissa S; Kassim S; El-Ahmady O
    Curr Opin Obstet Gynecol; 2003 Oct; 15(5):395-403. PubMed ID: 14501243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.